SCHEMBL5881980

SCHEMBL5881980

COCc1[nH]c2ccc(C(=O)O)cc2c1Cc1ccc(Cl)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.46
PTPN5 P54829 1/20 0.44
NR4A1 P22736 1/20 0.43
NR4A3 Q92570 1/20 0.43
SIRT1 Q96EB6 4/20 0.43
SIRT2 Q8IXJ6 1/20 0.43
MRGPRX4 Q96LA9 3/20 0.42
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TTR P02766 1/20 0.40
PPARG P37231 1/20 0.39
ALDH1A1 P00352 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
ALOX5 P09917 1/20 0.39
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5881795 0.91 MEN1 (0.52) NR4A2SIRT1SIRT2KDM4EMEN1
SCHEMBL5881808 0.88 SIRT1 (0.49) NR4A2PTPN5NR4A1NR4A3SIRT1
SCHEMBL5881838 0.86 MEN1 (0.51) NR4A2PTPN5NR4A1NR4A3SIRT1
SCHEMBL5881620 0.83 PTPN5 (0.57) NR4A2PTPN5MRGPRX4KDM4EMEN1
SCHEMBL5882328 0.81 MEN1 (0.56) SIRT1SIRT2KDM4EMEN1KMT2A
SCHEMBL5881739 0.81 KDM4E (0.43) NR4A2PTPN5NR4A1NR4A3SIRT1
SCHEMBL5881719 0.80 PPARG (0.49) SIRT1MEN1KMT2AATML3MBTL1
SCHEMBL5881925 0.79 MEN1 (0.69) NR4A2SIRT1SIRT2KDM4EMEN1
SCHEMBL5881887 0.76 KDM4E (0.50) PTPN5KDM4EMEN1KMT2AATM
SCHEMBL5882133 0.74 SPR (0.45) NR4A2NR4A1NR4A3SIRT1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT NR4A2 3386/4885PTPN5 2703/4885NR4A1 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.